epileptic seizures Archives - Amazing Health Advances

Do I Need an Epileptologist?

The AHA! Team — Mon, 18 Aug 2025 05:37:03 +0000

Morgan deBlecourt via Duke Health – An epileptologist is a neurologist who specializes in caring for people with epilepsy. Epileptologists have completed an additional one to two years of subspecialty training in epilepsy care. Most people with epilepsy can see a primary care doctor or general neurologist to manage their seizures. However, you may need more advanced care if your seizures are not under control, if you have certain medical issues, or if you want a second opinion. An epileptologist is a neurologist who specializes in caring for people with epilepsy. Epileptologists have completed an additional one to two years of subspecialty training in epilepsy care. When to See an Epileptologist To confirm your epilepsy diagnosis If your seizures are not under control after three months of care by your primary care physician or after one year of care by a general neurologist If your seizures are not under control despite trying two or three different medications If you are experiencing unwanted side effects from medications If you have other medical conditions or considerations that affect or are affected by epilepsy If you are pregnant or want to become pregnant Seek Care at an Epilepsy Center “An epileptologist typically works in a designated epilepsy center, which is capable of evaluating people whose seizures are not under adequate control. An epilepsy center provides a very comprehensive approach to care,” said Duke epileptologist Aatif Husain, MD. An epilepsy center is staffed by specialists who use sophisticated testing to pinpoint your diagnosis, offer the latest treatments, address possible side effects of medications, recommend surgical options if appropriate, and help you manage the social and emotional aspects of epilepsy. “Advances over the past decade have enabled more personalized epilepsy care,” said Duke epileptologist Birgit Frauscher, MD. “With new options now available, regular re-evaluation of treatment is essential.” As a Level 4 Epilepsy Center, Duke is recognized by the National Association of Epilepsy Centers for providing the highest level of diagnostic, treatment, and surgical options. To read the original article click here.

The post Do I Need an Epileptologist? appeared first on Amazing Health Advances.

Robot Reduces Need for Open Brain Surgery to Map Epileptic Seizures

The AHA! Team — Fri, 03 Jan 2025 07:38:39 +0000

Debbe Geiger via Duke Health – A Medical Advance for People with Epilepsy. A robotic device is allowing doctors to pinpoint the origins of a person’s seizures through minimally invasive surgery. The device, in use at Duke and some epilepsy centers across the country, allows neurosurgeons to implant hundreds of recording electrodes into the brain through about 10 to 20 small incisions. The procedure is highly precise, and it takes less time than traditional surgical options for seizure localization. People also recover faster and have less pain. Diagnosing the Origin of Epilepsy Seizures When medications fail to stop epileptic seizures, a person’s best hope for gaining control of their seizures is often epilepsy surgery. That can only happen if doctors can identify the area of the brain responsible for the seizures and remove it safely. To identify that spot, neurosurgeons may perform a craniotomy, creating a large opening in the skull, and then place a plastic grid of electrodes on the surface of the brain to record seizures and identify where they originate. However, the electrodes can’t access the folds or the parts of the brain between the two hemispheres and its deep structures. Shorter, More Precise Brain Mapping The team at Duke’s epilepsy center has another tool in their arsenal. Robot-assisted stereoelectroencephalography (SEEG) is a minimally invasive procedure that rapidly places thin electrode wires in precise locations to map the brain and identify seizure origins. A 3D reconstruction of the brain guides where the dozen or more electrodes will be placed. The neurosurgeon uses a robotic arm to make small, two- or three-millimeter holes in the scalp through which the rigid electrode wire is passed. As opposed to grid electrodes, which sit on the surface of the brain, the wires are placed into the brain tissue with robotic assistance. The procedure takes about two to three hours. “The robot improves the efficiency of the procedure, and it reduces some of the possibility for human error. Depending on the patient’s condition, robot-assisted SEEG can be very useful for localizing seizures in a way that is more comfortable for patients,” said Duke neurosurgeon Derek Southwell, MD, PhD, of the Duke Comprehensive Epilepsy Center. Due to its minimally invasive nature, placing depth electrodes this way is much better tolerated by patients than placing grid electrodes. Once the seizure origin is identified, the electrodes are removed, and people recover quickly. That is a huge benefit over recuperating from a craniotomy. The procedure is also better for cases where the exact location of the seizure cannot be identified, or the seizure origin is in a part of the brain that is inoperable. To read the original article click here.

The post Robot Reduces Need for Open Brain Surgery to Map Epileptic Seizures appeared first on Amazing Health Advances.

Eyelid Wearable Can Predict and Alert to Epileptic Seizure

The AHA! Team — Tue, 10 Sep 2024 09:00:10 +0000

John Jeffay via Israel21c – Blink Energy’s tiny device, fitted to one eyelid, monitors and analyzes blink patterns to detect or diagnose a wealth of health conditions. A tiny patch is fixed to your eyelid. It monitors your blink pattern and sends a warning to your smartphone that you’re about to have an epileptic seizure. Or that you’re about to fall asleep at the wheel. Or else it measures your REM (rapid eye movement) to help diagnose sleep disorders or Parkinson’s disease or a range of neurological conditions. This isn’t science fiction. This is the next step forward in the world of wearable technology. And according to Yariv Bar-On, CEO at Israel-based Blink Energy, it’s a gamechanger. The wearables market has been dominated, so far, by smartwatches and fitness trackers. The first Apple Watch was launched in April 2015, and wearable technology now includes jewelry that tracks your steps and notifies you of an incoming call, VR headsets for gamers, earbuds, smart glasses with Internet access, smart clothing integrated with electronic devices and a range of health monitors. But the world’s first eyelid wearable device opens up a whole new world of opportunity. Blink patterns Blink Energy’s device weighs just 0.4 grams (0.014 ounces) — less than half the weight of a paperclip – and is fitted to one eyelid. You barely notice it, says Bar-On. “After two minutes you forget it’s there.” But it’s performing an important function by monitoring blink patterns, which provides AI with a wealth of data. “There is one type of muscle that closes the eye, and another that opens it,” says Bar-On, an optometrist and entrepreneur. “There’s a ratio between those two muscles when they are working, and we can, with AI machine learning, identify abnormalities in the patterns of blinks.” Smartwatches and other devices measure eye movement indirectly, by collecting related data. Bar-On says they are only 80 percent accurate. His blink patch provides, for the first time, a way of readily measuring eye movement directly. He says he hopes to launch the company’s first product commercially within two years, at what he describes as an “affordable” price. Starting with epilepsy The possibilities for such technology, developed with his small team of engineers in Haifa, northern Israel, are many. The patch, held onto the eyelid with a disposable adhesive strip that lasts for 10 or 20 uses, can provide data about eye health or eye strain during the course of everyday activities. It can detect drowsiness at the wheel and has other possible uses in health and wellbeing. But the company had to start somewhere. And that somewhere is epilepsy. Bar-On wants to lessen the anxiety that people with epilepsy suffer. “My goal would be to bring epileptic patients more confidence in their daily life,” he tells ISRAEL21c. “You just wear it outside the house, knowing you don’t have to think about when the next seizure might be. The Blink device will indicate a few seconds before a seizure. But it’s not so much the detection as the fact that the wearer doesn’t have to worry about when the next seizure will be,” he says. “Knowing that the device will do that, instead of you having to, makes a big difference. Epileptic patients feel when the seizure is coming, but we can dramatically reduce the anxiety levels, which in themselves contribute to a seizure.” Blink Energy has yet to test its device on epileptic patients. The patch exists as a prototype, but there are still refinements needed before it’s ready for market. Eye mavens Bar-On cofounded Blink Energy four years ago with Nadav Cohen, a specialist in optics and vibrations, and Ziv Rotfogel, an ophthalmologist at Kaplan Medical Center in Rehovot, central Israel. “We wanted to see how we can look at the eye movement or the physiological signals that can be detected from the eye and develop a product that is beyond what it is on the market today,” he says. At first their focus was on using the blink movement to power the patch – which is why they chose the name Blink Energy. “We made a pivot almost two years ago and we developed our own sensor biomarker [which measures biological activity] with communication capabilities but without generating its own power,” he says. The product will recharge inside its own box, just like a pair of earbuds. “It’s not a me-too technology. It’s more like a really game-changing technology. I believe that in the next five to 10 years to come you’ll see many people walking down the street wearing an eyelid patch,” Bar-On predicts. “The adoption rate of wearable tech or smart wearables is already immense. This is just the start.” Blink Energy has received funding from the Israel Innovation Authority and by Israel-based MindUP, which invests in healthcare innovation. For more information, click here. To read the original article click here.

The post Eyelid Wearable Can Predict and Alert to Epileptic Seizure appeared first on Amazing Health Advances.

Melatonin Could Be a Potential Therapy for Long-COVID Symptoms

AHA Publisher — Thu, 17 Nov 2022 08:00:30 +0000

Dr. Chinta Sidharthan via News-Medical – A recent review published in the journal Biomolecules discussed the potential uses of melatonin in treating brain fog and chronic fatigue syndrome or myalgic encephalomyelitis symptoms associated with long coronavirus disease (COVID). Background An emerging concern associated with the coronavirus disease 2019 (COVID-19) pandemic is long COVID or clinical sequelae consisting of chronic fatigue, memory loss, muscle weakness, reduced pulmonary capacity during exertion, persistent fever, myalgia, epileptic seizures, stroke, and other cardiovascular complications. Patients who have recovered from severe COVID-19 experience these debilitating symptoms for months after recovery. Furthermore, studies that examined vaccinated individuals who experienced breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections found a high incidence of long COVID symptoms such as deteriorated musculoskeletal, neurological, and mental health among these individuals after recovery. This indicates that vaccination provides only limited protection against long COVID. Melatonin is a cryoprotective hormone and chemical that exhibits anti-inflammatory, antioxidant, and immunoregulatory activity and has been seen to impair viral infections, play a role in circadian rhythm maintenance, and be effective against diabetes mellitus and cardiovascular diseases. It is also involved in the activation of glutathione-synthesizing enzymes. Melatonin could potentially be a therapeutic agent in treating long COVID symptoms. Long COVID Symptoms Brain fog is a general term used to defineimpaired cognitive function, such as difficulty concentrating, loss of working and short-term memory, and difficulty with verbal and non-verbal methods of learning and mathematical problem-solving. While brain fog can be a consequence of various factors such as sleep deprivation, malnutrition, pregnancy or menopause-related hormonal changes, or even chemotherapy, it was the most reported symptom among COVID-19-recovering patients with no history of other diseases or hypoxia. An intelligence test in the United Kingdom detected cognitive impairments in a significant number of individuals with COVID-19. Symptoms included memory loss, disorientation, and reduced mental energy. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is characterized by excessive and persistent fatigue, inability to perform physical exercise, and autonomic dysregulation. ME/CFS is also associated with disruption of circadian rhythms and the gut/mucosal barrier, mitochondrial dysfunction, and a pro-inflammatory state. Studies indicated that 45% of COVID-19 patients who were hospitalized and required intensive care unit admission exhibited ME/CFS symptoms up to six months after recovery. Melatonin as a Potential Long COVID Treatment Melatonin is a hormone naturally produced in all aerobically respiring life forms, and it performs antioxidant, anti-inflammatory, immunostimulant, and neuroprotective functions in the body. It reduces the pro-inflammatory response of macrophages, activates nuclear erythroid 2-related factor 2, and suppresses the activation of nuclear factor (NF)-κB. Melatonin is also known to balance inflammatory responses by decreasing the levels of pro-inflammatory cytokines such as interleukins (IL) 1β, 6, and 8, and tumor necrosis factor (TNF)-α, and increasing anti-inflammatory cytokine IL-10. Warburg’s effect during viral infections causes a shift from mitochondrial oxidative phosphorylation to glycolysis which occurs in the cytoplasm. This is accompanied by inflammation-promoting mechanisms such as an increase in NF-κB and hypoxia-inducible factor-1α. Consequently, the anti-inflammatory M2 macrophages are converted to pro-inflammatory M1 macrophages, causing a cytokine storm known to cause endothelial tissue and organ damage in severe COVID-19 patients. The anti-inflammatory effects of melatonin in preventing pro-inflammatory profiles or macrophages and suppressing NF-κB activation can help reverse Warburg’s effect in long COVID patients. Melatonin also regulates the amyloid β (Aβ) metabolism associated with Alzheimer’s disease. Studies with transgenic Alzheimer’s disease models have shown that melatonin can control neuroinflammation by interacting with Aβ40 and Aβ42 and increasing protein degradation. Furthermore, the ability of melatonin to regulate circadian rhythms and sleep patterns has been shown to improve cognitive function and sleep in patients in the early stages of cognitive decline. Melatonin is also known to exhibit therapeutic activity against the various symptoms of ME/CFS, such as oxidative stress, pro-inflammatory state, mitochondrial and bioenergetic dysregulation, and disruption of the gut/mucosal barrier. Conclusions Overall, the review reported the significant potential for the use of melatonin in long-COVID and COVID-19 therapy. Studies have shown melatonin is more effective in reducing COVID-19 inflammatory markers than commonly used SARS-CoV-2 antivirals. The authors believe that although melatonin exhibits anti-inflammatory and immunostimulant properties that many studies have reported being effective against COVID-19, it has not been promoted as a therapeutic option, possibly due to its easy availability and non-patentability, which makes it an unattractive target for pharmaceutical industries. They recommend clinical trials to explore the use of melatonin as a treatment for long COVID symptoms. To read the original article click here.

The post Melatonin Could Be a Potential Therapy for Long-COVID Symptoms appeared first on Amazing Health Advances.